[ Genoa Pharmaceuticals raises $62M in Series A ]
Genoa Pharmaceuticals has raised $62 million in Series A funding.
Founded in 2011, Genoa Pharmaceuticals is a biopharma firm that develops therapies for the treatment of idiopathic pulmonary fibrosis and respiratory diseases.Genoa’s lead program (Aerodone™; inhaled pirfenidone) is on track to enter clinical development by year’s end
With this financing and its veteran development team, the company has the funds and expertise to test Aerodone™ for the treatment of IPF through Phase 2 clinical trials.
|Founder / CEO||Bruce Montgomery|
|Edmond de Rothschild Investment Partners|
|F-Prime Capital Partners|